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Platelet activation via Fc receptor IIA
(FcRIIA) is a critical event in immune-
mediated thrombocytopenia and thrombo-
sis syndromes (ITT). We recently identi-
fied signaling by the guanine nucleotide
exchange factor CalDAG-GEFI and the
adenosine diphosphate receptor P2Y12
as independent pathways leading to Rap1
small GTPase activation and platelet ag-
gregation. Here, we evaluated the contri-
bution of CalDAG-GEFI and P2Y12 signal-
ing to platelet activation in ITT. Mice
transgenic for the human FcRIIA
(hFcR) and deficient in CalDAG-GEFI/
(hFcR/CDGI/) were generated. Com-
pared with controls, aggregation of hFcR/
CDGI/ platelets or P2Y12 inhibitor-
treated hFcR platelets required more than
5-fold and approximately 2-fold higher
concentrations of a FcRIIA stimulating
antibody against CD9, respectively. Aggre-
gation and Rap1 activation were abol-
ished in P2Y12 inhibitor-treated hFcR/
CDGI/ platelets. For in vivo studies, a
novel model for antibody-induced throm-
bocytopenia and thrombosis was estab-
lished. FcRIIA-dependent platelet throm-
bosis was induced by infusion of
Alexa750-labeled antibodies to glycopro-
tein IX (CD42a), and pulmonary thrombi
were detected by near-infrared imaging
technology. Anti-GPIX antibodies dose-
dependently caused thrombocytopenia
and pulmonary thrombosis in hFcR-
transgenic but not wild-type mice.
CalDAG-GEFI-deficient but not clopidogrel-
treated hFcR-transgenic mice were com-
pletely protected from ITT. In summary,
we established a novel mouse model for
ITT, which was used to identify CalDAG-
GEFI as a potential new target in the
treatment of ITT. (Blood. 2011;118(4):
1113-1120)
Introduction
Platelets are essential components of the hemostatic response to
vascular injury. However, platelets also play a role in pathologic
conditions, such as atherothrombosis, and in immune-mediated
thrombocytopenia and thrombosis (ITT). Several ITT syndromes,
including heparin-induced thrombocytopenia and thrombosis
(HIT),1-3 bacterial sepsis-associated thrombocytopenia and dissemi-
nated intravascular coagulation,4,5 and the thrombotic manifesta-
tions of antiphospholipid syndromes6 are characterized by immune-
mediated platelet activation through the platelet Fc receptor,
FcRIIA. In addition, thrombotic complications have been ob-
served with the expanded use of therapeutic IgG antibodies, such as
bevacizumab.7-9 One of the barriers to successful treatment of these
thrombotic syndromes is that therapeutic targeting of platelet
activation pathways to prevent thrombosis is either not effective or
comes with an inherent risk of bleeding complications.
In humans, FcRIIA is expressed on platelets, neutrophils,
monocytes, and macrophages and activates these cells following
the binding of the Fc region of IgG-coated cells or IgG-containing
immune complexes.10 Mice lack the genetic equivalent of human
FcRIIA and, indeed, do not express a platelet Fc receptor.
Consequently, most of the studies on the role of FcRIIA in platelet
activation were entirely dependent on the use of inhibitors, and
they did not provide information on whether or not these inhibitors
would reduce the risk of excessive platelet activation as observed in
the clinical settings of ITT or HIT. To circumvent this limitation,
we generated and characterized human FcRIIA-transgenic (hFcR)
mice in which FcRIIA is expressed on mouse platelets and
macrophages at levels equivalent to that in human cells.11 For
studies on HIT, we further crossed hFcR mice with mice deficient
for mouse PF4 but transgenic for human PF4.12 Using these mouse
models, we demonstrated a critical role for FcRIIA expression in
antiplatelet antibody-induced and heparin-induced thrombocytope-
nia and thrombosis in vivo.11-14
FcRIIA is unique among the activating Fc receptors in that its
cytoplasmic tail contains an immunoreceptor tyrosine-based activa-
tion motif.15 Residues in the immunoreceptor tyrosine-based
activation motif domain become rapidly phosphorylated on recep-
tor engagement and induce cell activation after binding by nonre-
ceptor protein tyrosine kinases, such as spleen tyrosine kinase.16,17
It is widely accepted that stimulation of FcRIIA on platelets
stimulates spleen tyrosine kinase, leading to PLC activation and
the generation of the second messengers Ca2 and DAG. In our
recent work, we have described a central role for Ca2 and
diacylglycerol regulated guanine nucleotide exchange factor
I (CalDAG-GEFI) in Ca2-dependent platelet activation.18-21
CalDAG-GEFI catalyzes the activation of the small GTPases
Ras-proximate (Rap)1 and Rap2. In platelets, Rap1B accounts for
90% of the total Rap protein,22 and its importance in IIb3
activation was demonstrated in Rap1B-deficient mice.23 Our stud-
ies with CalDAG-GEFI/ mice in combination with inhibitors to
protein kinase C or the Gi-coupled adenosine diphosphate receptor,
P2Y12, identified a 2-pathway model for integrin activation
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downstream of PLC activation. CalDAG-GEFI is a high-affinity
sensor for Ca2, which mediates the rapid but reversible activation
of IIb3. In the absence of CalDAG-GEFI, Rap1/integrin activa-
tion is delayed but sustained and depends on signaling by protein
kinase C and P2Y12. Notably, our studies further suggested that
CalDAG-GEFI is particularly important for platelet activation
through GPVI, the immunoreceptor tyrosine-based activation motif-
coupled platelet collagen receptor.21
In this study, we evaluated the contribution of 2 critical platelet
signaling pathways, Ca2/CalDAG-GEFI/Rap1 and P2Y12/Rap1,
to platelet activation in ITT. Deficiency in CalDAG-GEFI, and to a
lesser extent inhibition of P2Y12, provided protection from
FcRIIA-mediated platelet aggregation both in vitro and in vivo.
Methods
Reagents and antibodies
Lovenox (enoxaparin sodium; Sanofi-Aventis), heparin-coated capillaries
(VWR), BSA (fraction V), prostacyclin, human fibrinogen (type I),
acetylsalicylic acid (aspirin; all from Sigma-Aldrich), 2-methylthio-AMP
triethylammonium salt hydrate (2-MeSAMP, P2Y12 inhibitor, BioLog),
U46619 (Cayman Chemical), PAR4-activating peptide (Advanced
Chemtech), TxB2 immunoassay (Assay Design), and RalGDS-RBD coupled
to agarose beads and polyvinylidene fluoride membranes (Millipore) were
purchased. Monoclonal antibodies against murine CD9 (rat IgG2a, BD
Biosciences Pharmingen) and murine GPIX, GPIb, IIb3, GPVI,
1 integrin, control IgG (Emfret Analytics), murine Rap1 (Santa Cruz
Biotechnology), human FcRIIA (IV.3, StemCell Technologies), and goat
anti–mouse IgG (Fab2; Santa Cruz Biotechnology) were purchased.
Mice
Mice transgenic for hFcRIIA,11 CalDAG-GEFI/,18 and littermate con-
trol wild-type (WT) mice were bred on a C57Bl6/J strain background and
housed in the mouse facility of Thomas Jefferson University. Experimental
procedures were approved by the Animal Care and Use Committee of
Thomas Jefferson University. Where indicated, mice were treated with
clopidogrel 24 and 3 hours before the experiment at a dosage of 75 mg/kg
body weight orally by gavage feeding.
Platelet preparation
Blood was drawn from the retroorbital plexus into heparinized tubes.
Platelet-rich plasma (PRP) was obtained by centrifugation at 100g for
5 minutes at room temperature. PRP was centrifuged at 700g in the presence
of prostacyclin (2 g/mL) for 5 minutes at room temperature. After
2 washing steps, pelleted platelets were resuspended at the concentration of
4  108 platelets/mL in modified Tyrode buffer (137mM NaCl, 0.3mM
Na2HPO4, 2mM KCl, 12mM NaHCO3, 5mM HEPES, 5mM glucose, pH
7.3) containing 0.35% BSA and 1mM CaCl2.
Flow cytometry
Surface expression of FcRIIA. Blood was obtained from the retro-
orbital plexus of anesthetized mice. Blood samples were stained with a
phycoerythrin-labeled antibody against GPIb and an Alexa488-labeled
antibody against FcRIIA (IV.3). Surface expression of FcRIIA was
determined as the mean fluorescence intensity in channel 1 (FL-1) for all
events that stained positive for FL-2.
Platelet count. Blood samples were stained with a phycoerythrin-
labeled antibody against IIb3, and platelets were counted by flow
cytometry gating for FL-2 (phycoerythrin) positive events. Platelet counts
at t 	 0 were defined as 100%.
Aggregometry
Light transmission was measured in PRP or washed platelets activated
under stirring conditions at 37°C. Inhibitors and agonists were added at the
indicated concentrations, and light transmission was recorded for 10 to
15 minutes on a Chrono-log 4-channel optical aggregation system
(Chronolog).
Rap1 pull-down assay
Platelets were stimulated in standard aggregometry for 1 or 10 minutes.
Reactions were stopped with ice-cold 2 lysis buffer (100mM Tris/HCl,
pH 7.4, 400mM NaCl, 5mM MgCl2, 2% Nonidet P-40, 20% glycerol, and
complete protease inhibitor cocktail lacking ethylenediaminetetraacetic
acid). Cell lysis was completed on ice for 15 minutes. Rap1-GTP was
precipitated from lysates using RalGDS-RBD beads as described previ-
ously.18 Pellets were solubilized in sample buffer (75mM Tris/HCl pH 6.8,
10% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.004% bromophenol
blue) for the detection of Rap1 by immunoblot. Small aliquots were saved
to control that each sample contained equal amounts of proteins.
Western blotting
Proteins were separated by SDS-PAGE on 10%-20% gradient gels and
transferred to polyvinylidene fluoride membranes. Standard Western blot-
ting procedures were used. Rap1 was detected, and band intensity was
quantified with the Odyssey Infrared Imaging System (LICOR Biosystems).
Thromboxane generation assay
Platelets were stimulated in standard aggregometry. At different time
points, 50 L of sample was withdrawn and 5mM EDTA /1mM acetylsali-
cylic acid was added. The cells were removed by centrifugation, and TxB2
levels were determined in the supernatant by enzyme immunoassay. TxB2 is
the stable product of the nonenzymatic hydration of thromboxane (TxA2),
which itself has a half-life of only 37 seconds under physiologic conditions.
In vivo immunoglobulin-mediated thrombosis model
Animals were matched according to their platelet Fc-receptor expression
before the experiment. Mice were anesthetized with isoflurane, and
anti–GPIX-750 was administered by retro-orbital injection at a dose of
0.5 g/g or 1 g/g body weight. After 4 hours, the mice were anesthetized
and killed by cervical dislocation. Laporotomy and thoracotomy were
performed to gain access to the internal organs. The organs were carefully
flushed with 2 mL PBS by left ventricular and right ventricular puncture to
perfuse the lung and systemic vessels. After flushing, the organs were
harvested, cleared from fatty and connective tissue, and incubated in
4% paraformaldehyde for 24 hours before they were read on a conventional
LICOR Odyssey scanner (LICOR).
Pearl imaging method. WT animals and hFcR animals were anesthe-
tized with 100 mg/kg ketamine (Fort Dodge Animal Health) and 10 mg/kg
xylazine (Lloyd Lab), the abdominal and thoracic region was shaved with
an electric clipper, and the remaining hair was removed with a depilatory
cream. Subsequently, the mice were injected with an anti–GPIX-750
antibody. After 4 hours, bio imaging was performed using a Pearl Impulse
in vivo imaging chamber (LICOR Biosystems) at 800 nm.
H&E staining. Extracted lungs were cryosectioned (8-m sections)
and stained with H&E at the histology core within the Pathology
Department at Thomas Jefferson University.
Statistics
Results are reported as mean 
 SEM. Statistical significance was assessed
by unpaired 2-tailed Student t test. A P value  .05 was considered
significant.
Results
To evaluate the role of CalDAG-GEFI in FcRIIA-mediated
platelet activation, we generated mice transgenic for hFcR and
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deficient in CalDAG-GEFI (hFcR/CDGI/). Staining of platelets
for surface-expressed FcRIIA demonstrated variation in its expres-
sion level from mouse to mouse. Thus, for further experiments, we
selected mice with similar platelet FcRIIA expression (Figure 1).
Importantly, the surface expression of GPIb, GPIX, GPVI,
IIb3 integrin, and 1 integrins on platelets from hFcR/CDGI/
mice did not differ significantly compared with platelets from
WT or hFcR mice (supplemental Table 1, available on the Blood
Web site; see the Supplemental Materials link at the top of the
online article).
In a first step, we evaluated the contribution of CalDAG-GEFI
and P2Y12 to FcRIIA-mediated platelet aggregation. Confirming
previous results,14 addition of antibodies to the cell surface protein
CD9 led to rapid, integrin IIb3-dependent aggregation of
hFcR-transgenic but not WT platelets (Figure 2A). hFcR/CDGI/
platelets did not aggregate in response to low-dose anti-CD9
(1g/mL, Figure 2B top panel), and aggregation induced by
high-dose anti-CD9 (10g/mL, Figure 2B bottom panel) was
markedly delayed compared with hFcR platelets. Compared with
hFcR/CDGI/ platelets, hFcR platelets treated with the P2Y12
inhibitor 2-MeSAMP showed a more robust aggregation response
both at the low and the high dose of the agonist. Aggregation was
abolished in hFcR/CDGI/ platelets pretreated with 2-MeSAMP,
confirming that signaling by both CalDAG-GEFI and P2Y12 is
Figure 1. Surface expression of human FcRIIA. (A) Representative histograms for platelets from a WT mouse (dashed black trace) and a mouse transgenic for the hFcR
(black trace) stained with IV.3-Alexa488. (B) FcRIIA expression levels on platelets from hFcR mice and mice transgenic for hFcR and deficient in CalDAG-GEFI
(hFcR/CDGI/). Only mice with a platelet mean fluorescence signal (IV.3-Alexa488) between 100 and 150 were used for further experiments.
Figure 2. CalDAG-GEFI deficiency protects from FcRIIA-dependent platelet aggregation. (A-B) Representative aggregation traces in response to anti-CD9. (A) WT
(black dashed line) and transgenic hFcR platelets were stimulated with 5 g/mL anti-CD9 in the presence (dotted black line) or absence (black line) of 75 g/mL of the IIb3
blocking antibody Leo.H4. (B) Black line represents hFcR; light gray line, hFcR treated with the P2Y12 inhibitor 2-MeSAMP; dark gray line, hFcR/CDGI/; and dashed dark
gray trace, hFcR/CDGI/ treated with 2-MeSAMP. Platelets were stimulated with low-dose (top panel, 1 g/mL) or high-dose (bottom panel, 10 g/mL) anti-CD9. Traces are
representative of 3 independent experiments. (C) Dose-response of anti–CD9-induced platelet aggregation. Maximum aggregation (%, top panel) and delay of aggregation
(minutes, bottom panel) measured in PRP from hFcR (black bar), hFcR preincubated with 100M 2-MeSAMP (light gray bar), and hFcR/CDGI/ platelets (dark gray bar)
stimulated with increasing doses of anti-CD9 antibodies. Data are mean
 SEM (n 	 5 or 6). *P  .05. **P  .01. (D) Maximum aggregation measured in PRP from WT (black
bar), WT preincubated with 100M 2-MeSAMP (light gray bar), and CDGI/ platelets (dark gray bar) stimulated with increasing doses of PAR4 receptor-activating peptide.
Data are mean
 SEM (n 	 5).
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required for FcRIIA-mediated platelet activation (Figure 2B
bottom panel). Importantly, dose-response studies with anti-CD9
antibodies revealed that maximum aggregation in hFcR/CDGI/
platelets required more than 5-fold higher concentrations of
anti-CD9 compared with hFcR platelets. Addition of 2-MeSAMP
caused only an approximately 2-fold shift in the dose-response to
anti-CD9 in hFcR platelets (Figure 2C top panel). Furthermore, the
delay in the aggregation response observed in hFcR/CDGI/
platelets was significantly greater than that in 2-MeSAMP–treated
and untreated hFcR platelets (Figure 2C bottom panel). In contrast,
aggregation of both CDGI/ and 2-MeSAMP–treated WT plate-
lets required only 2-fold higher concentrations of PAR4 receptor-
activating peptide (Par4p) compared with untreated WT platelets
(Figure 2D). Thus, CalDAG-GEFI is particularly important for
FcRIIA-dependent platelet activation. To confirm this result, we
directly cross-linked FcRIIA with the monoclonal antibody IV.3
and anti-IgG (Fab2) fragments (supplemental Figure 1). Aggrega-
tion was observed with hFcR platelets but not hFcR/CDGI/
platelets stimulated with 2 g/mL IV.3 and 30 g/mL anti-IgG
(Fab2). Inhibition of P2Y12 in hFcR platelets partially inhibited
aggregation at this dose (top panel). At 8 g/mL IV.3 and
60 g/mL anti-IgG (Fab2), aggregation was still reduced in
hFcR/CDGI/ platelets, whereas normal aggregation was ob-
served in 2-MeSAMP–treated hFcR platelets (bottom panel). At
both agonist concentrations, aggregation was completely abolished
in 2-MeSAMP–treated hFcR /CDGI/ platelets.
In agreement with our recent studies on the role of CalDAG-
GEFI and P2Y12 in Rap1 activation in platelets stimulated via the
receptors for thrombin, PAR4, or collagen, GPVI,20,21 we observed
impaired Rap1 activation downstream of FcRIIA in hFcR/
CDGI/ or 2-MeSAMP–treated hFcR platelets (Figure 3A-B).
More specifically, hFcR/CDGI/ platelets lacked the early phase
of Rap1 activation, whereas 2-MeSAMP–treated hFcR platelets
were defective in sustained activation of the small GTPase. Rap1
activation was completely abolished in 2-MeSAMP–treated hFcR/
CDGI/ platelets. An important platelet response controlled by
Rap1 is the generation of the second wave mediator thromboxane
(TxA2).21 As expected, the generation TxB2, a stable analog of
TxA2, was almost completely abolished in 2-MeSAMP–treated
hFcR/CDGI/ platelets (Figure 3C). Deficiency in CalDAG-GEFI
led to a significant reduction in TxB2 formation, whereas inhibition
of P2Y12 alone did not affect TxB2 release under these experimen-
tal conditions. Importantly, addition of an exogenous thromboxane
analog (U46619) restored aggregation in hFcR/CDGI/ platelets
activated with a threshold dose of anti-CD9 antibodies, whereas
either agonist alone failed to induce aggregation (Figure 3D).
Inhibition of TxA2 generation by the COX-1 inhibitor acetylsali-
cylic acid (aspirin), however, had only a mild inhibitory effect on
the aggregation of both hFcR and hFcR/CDGI/ platelets (supple-
mental Figure 2). This impairment was much weaker than that
observed in hFcR/CDGI/ platelets in response to anti-CD9
(Figure 2), indicating that (1) CalDAG-GEFI predominantly af-
fects FcRIIA-dependent platelet aggregation because of its criti-
cal role in integrin IIb3 activation, and (2) the defect in TxA2
feedback is critical only in the absence of CalDAG-GEFI-mediated
integrin activation.
Next, we sought to determine the contribution of CalDAG-
GEFI and P2Y12 signaling to FcRIIA-mediated platelet activa-
tion in ITT. In our previous work, we showed that infusion of
antibodies against CD9 (rat IgG2a isotype) causes thrombocytope-
nia in mice independent of FcRIIA and that FcRIIA-independent
Figure 3. CalDAG-GEFI synergizes with P2Y12 signaling in Rap1 activation downstream of FcRIIA. (A) Time course of Rap1 activation on stimulation of hFcR and
hFcR/CDGI/ platelets with 10 g/mL anti-CD9 in the absence or presence of 100M 2-MeSAMP. (Bottom panel) Total Rap1 as loading control. (B) Densitometric analysis of
Rap1-GTP shown as percentage of maximal activation (mean 
 SEM, n 	 3). (C) TxB2 levels in the supernatant of hFcR and hFcR/CDGI/ platelets 4 minutes after
stimulation with 5 g/mL anti-CD9 in the absence or presence of 100M 2-MeSAMP. Data are mean 
 SEM (n 	 6). *P  .05. ***P  .001. ns indicates not significant.
(D) Aggregation response of hFcR/CDGI/ platelets activated with 1 g/mL anti-CD9, 5M U46619 (TxA2 analog), or the combination of both agonists. Traces are
representative of 4 independent experiments.
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platelet consumption protects mice from FcRIIA-mediated throm-
botic complications.14 We also showed that antibodies to membrane-
proximal domains within the GPIb-IX subunit of the von Wille-
brand factor receptor complex have minimal effects on the survival
of circulating platelets in regular WT mice, irrespective of their
isotype.24,25 Thus, we speculated that antibodies to GPIX could be
well suited to induce FcRIIA-dependent thrombocytopenia and
thrombosis in mice. In vitro, antibodies to GPIX caused aggrega-
tion of U46619-primed hFcR but not hFcR/CDGI/ platelets
(Figure 4A). Inhibition of P2Y12 signaling partially inhibited
anti-GPIX–induced aggregation of hFcR platelets. Consistent with
these findings, we observed that anti-GPIX antibodies induced
Rap1 activation in hFcR platelets only in the presence of U46619.
Whereas Rap1 activation induced by anti-GPIX/U46619 was
abolished in hFcR/CDGI/ platelets, it was partially reduced in
2-MeSAMP–treated hFcR platelets (Figure 4B).
Infusion of antibodies to GPIX dose-dependently caused severe
thrombocytopenia in hFcR but not regular WT mice (Figure 5A),
and thrombocytopenia was associated with the formation of
pulmonary microthrombi (Figure 5B). To quantify thrombus forma-
tion in the lungs, we injected mice with Alexa750 fluorophore-
coupled antibodies to GPIX followed by near-infrared scanning of
the whole animal (Figure 5B) or isolated lungs (Figure 6).
When scanned on a Pearl in vivo Imaging Chamber (LICOR)
4 hours after infusion of the antibody, WT mice did show
accumulation of the fluorescence dye in the liver and spleen, but
not in the thorax. However, when injecting hFcR mice with the
labeled GPIX antibody, there was a distinct accumulation of
fluorescence in the thorax (Figure 5B), suggesting the formation of
platelet-rich thrombi in the lungs. H&E-stained histology sections
of extracted lungs confirmed the formation of microthrombi rich in
platelets and fibrin (Figure 5B inset). For studies on the role of
CalDAG-GEFI and P2Y12 in experimental ITT, we decided to
quantify ITT in lungs extracted 4 hours after infusion of the
antibody. At a dosage of 0.5 g/g body weight of the antibody, both
hFcR/CDGI/ mice and clopidogrel-treated hFcR mice were
completely protected from thrombocytopenia (Figure 6A) and
pulmonary thrombosis (Figure 6C,E) compared with hFcR mice.
At 1 g/g body weight, however, hFcR/CDGI/ mice were still
protected from ITT, whereas clopidogrel treatment did not signifi-
cantly affect pulmonary thrombosis in hFcR mice. hFcR mice
injected with 1 g/g anti-GPIX antibodies also displayed a shock
phenotype with marked tactile hypothermia (not shown), severely
reduced motor activity, and shallow, rapid, and irregular breathing
(supplemental Video). Clopidogrel treatment did not prevent these
anti-GPIX–induced shock-like symptoms in hFcR mice, whereas
no symptoms were observed in hFcR/CDGI/ mice.
Discussion
We here describe the generation of a novel mouse model for ITT, in
which Alexa750 fluorophore-labeled antibodies against the platelet
surface receptor GPIX are used (1) to selectively induce thrombo-
cytopenia and thrombosis in FcRIIA-positive but not WT FcRIIA-
negative mice and (2) to facilitate the rapid and quantitative
visualization of pulmonary thrombi by near-infrared imaging
technology. Using this cutting-edge technology, we were able to
demonstrate that FcRIIA-dependent platelet aggregation occurs
in the systemic venous system and/or the lungs of mice and that
Figure 4. CalDAG-GEFI deficiency protects from platelet aggregation induced by antibodies to GPIX. (A) Aggregation of hFcR (black line), hFcR pretreated with 100M
2-MeSAMP (light gray line), and hFcR/CDGI/ (dark gray line) platelets in response to 0.5 g/mL anti-GPIX in combination with a threshold dose of U46619 (0.25M).
Aggregation responses of hFcR platelets to either 0.5 g/mL anti-GPIX or 0.25M U46619 alone are shown for comparison. (B) Rap1 activation in hFcR and hFcR/CDGI/
platelets at t 	 15 minutes of stimulation with anti-GPIX (0.5 g/mL) and/or U46619 (0.25M) in the absence or presence of 100M 2-MeSAMP. (Bottom panel) Total Rap1 as
loading control. Representative of 3 independent experiments.
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pulmonary platelet accumulation was completely abolished in mice
transgenic for hFcRIIA but deficient in CalDAG-GEFI. In
contrast, clopidogrel bisulfate (Plavix) treatment only partially
inhibited ITT in mice.
Studies in mice on the mechanisms regulating immune-
mediated thrombosis have been difficult for several reasons. First,
mice do not express the activating Fc receptor, FcRIIA, on
circulating platelets and thus do not develop HIT/ITT. To circum-
vent this limitation, we previously generated and characterized
mice transgenic for the human FcRIIA receptor.11 Another
important limitation for studies on ITT in mice is based on the
ability of many antibodies directed against mouse platelet surface
receptors to induce thrombocytopenia independent of FcRIIA
expression. Platelet elimination by the reticuloendothelial phago-
cytic system, however, complicates studies on ITT, as FcRIIA-
independent platelet removal protects mice from FcRIIA-
dependent thrombosis.14 Clinically relevant antibodies/immune
complexes, such as the heparin/PF4/anti-PF4 complex12 or the
heparin/vascular endothelial growth factor (VEGF)/anti-VEGF
complex,7 however, do not cause thrombocytopenia in the absence
of platelet FcRIIA. Finally, there is a lack of technologies that
allow a simple but quantitative visualization of microvascular
thrombi in the vital organs of ITT mice. So far, most studies relied
on the peripheral platelet count in combination with hematoxylin
and eosin tissue sections as a read-out for thrombotic complica-
tions. We here describe a novel mouse model for ITT in FcRIIA-
transgenic mice, which showed good correlation to HIT and
antibody-induced thrombotic complications, both in vitro and in
vivo. Our model also markedly simplifies the detection of tissue
microthrombi, as it facilitates the quantitative visualization of
thrombosis in antibody-treated mice. We selected antibodies to
the GPIX subunit of the von Willebrand factor receptor complex
to induce thrombocytopenia and thrombosis in an FcRIIA-
dependent manner, as such antibodies show marginal effects on
circulating platelet counts in control mice compared with antibod-
ies against other platelet surface receptors, such as IIb3, GPIb,
or CD9.14,24,25 In mice transgenic for hFcR, however, anti-GPIX
antibodies caused severe thrombocytopenia within hours (Figure
5). Thrombocytopenia was accompanied by the formation of
fibrin-rich thrombi, particularly in the lungs (Figures 5-6), marked
tactile hypothermia, severely reduced motor activity, and shallow,
rapid, and irregular breathing. Very similar findings have been
made for hFcR/hPF4 double-transgenic mice after injection of
heparin and anti-PF4 antibodies (S.E.M., unpublished observation)
and for FcRIIA-transgenic mice treated with the antiangiogenic
drug bevacizumab in combination with VEGF and heparin.7
Importantly, patients with acute HIT can develop a plethora of
complications of arterial and venous thrombosis, including pulmo-
nary thromboembolism, stroke, and myocardial infarction. Consis-
tently, they can present with a variety of symptoms, including
dyspnea, neurologic deficiencies, chest pain, and shock.26,27
Interestingly, antibodies to GPIX are weak agonists for FcRIIA-
dependent mouse platelet activation/aggregation in vitro (Figure
4), similar to what has been described for immune complex-
mediated activation of these cells.7 Consistent with this observa-
tion, it is also widely known that preactivation of low responding
human platelets can produce positive FcRIIA-dependent aggrega-
tion responses to HIT complexes.28,29 Thus, our findings that
FcRIIA-dependent mouse platelet activation by anti-GPIX anti-
bodies benefits from priming of these cells are consistent with
Figure 5. Antiplatelet antibody-induced thrombocytopenia and thrombosis in vivo. (A) Platelet count of hFcR transgenic mice (solid line) injected with 0.5 g/g (f) or
1.0 g/g (Œ) body weight of anti-GPIX antibody. Platelet count of WT mice injected with anti-GPIX (1 g/g body weight) is shown as control (dashed line, F). The platelet counts
in whole blood were determined at baseline (t 	 0) and every hour up to 4 hours. Results shown are percentage platelet count compared with baseline. *P  .05. **P  .01.
***P  .001. (B) Whole-body scan with a Pearl in vivo Imager of hFcR mice and WT mice 4 hours after the injection of Alexa750-labeled anti-GPIX antibody (1 g/g body
weight) LICOR, Pearl infrared chamber, software Pearl cam Version 2.0. thx indicates thorax; lvr, liver; and spln, spleen. (Insets) Representative H&E-stained histology
sections of lungs isolated from WT or hFcR mice. Arrows point at fibrin and platelet-rich thrombi in the lung vasculature. Images are representative of 3 independent
experiments. Scale bar represents 50 m. The images were obtained with a Nikon Eclipse 80i microscope (Nikon) and a 40/0.8 numeric aperture oil-immersion objective
lens, imaging medium: oil, H&E staining, Spot Flex Color camera (Diagnostic Instruments), Spot Advanced Version 4.5 software (Diagnostic Instruments).
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observations on immune complex-mediated activation in human
and murine platelets.
We have previously demonstrated that CalDAG-GEFI is critical
for Ca2-dependent activation of Rap1 and IIb3 integrin in
platelets activated by thrombin or collagen, especially under
physiologic flow conditions.18,20,21 We here demonstrate that
CalDAG-GEFI is critical for FcRIIA-mediated activation of Rap1
and IIb3 in platelets stimulated by antibodies directed against
the surface receptors CD9, GPIX, or FcRIIA itself (Figures 2 and
4; supplemental Figure 1). Compared with hFcR control platelets,
aggregation of hFcR/CDGI/ platelets required only a 2-fold
increase in the concentration of PAR4 receptor-activating peptide,
whereas more than 5-fold higher concentrations of stimulating
antibodies (anti-CD9) were needed to aggregate hFcR/CDGI/
cells. Feedback activation via P2Y12, however, was equally
important for PAR4- and FcRIIA-dependent platelet activation, as
preincubation of hFcR platelets with 2-MeSAMP caused an
approximately 2-fold shift in the dose-response to PAR4p or
anti-CD9 antibodies. Consistent with previous findings on the role
of Ca2/CalDAG-GEFI signaling for platelet activation via the
collagen receptor, GPVI,21 TxA2 release from antibody-stimulated
hFcR/CDGI/ platelets was markedly reduced and addition of
exogenous TxA2 restored aggregation in hFcR/CDGI/ platelets
stimulated via FcRIIA. Importantly, inhibition of TxA2 synthesis
had only a minor effect on the aggregation response of hFcR
platelets, demonstrating that CalDAG-GEFI is critical for FcRIIA-
dependent platelet activation because of its critical role in both
integrin IIb3 activation and TxA2 biosynthesis, a finding that is
well in line with the documented role of TxA2 in FcRIIA-
mediated platelet activation.30,31
Consistent with these in vitro findings, we observed complete
protection from ITT in hFcR/CDGI/ mice, whereas clopidogrel
treatment was not effective when mice were challenged with a
higher dose of anti-GPIX antibodies. This limited protective effect
of clopidogrel in the setting of experimental ITT is in accordance
with clinical studies demonstrating incomplete protection from
HIT in patients receiving both aspirin and clopidogrel.32 Our
studies may explain the limited effect of P2Y12 inhibitors in the
setting of HIT/ITT. P2Y12 inhibitors affect the sustained activation
of Rap1, important for stable platelet adhesion at sites of vascular
injury. However, they do not affect the rapid, CalDAG-GEFI–
mediated activation of Rap1, which is sufficient for the formation
of reversible platelet aggregates under low and high shear stress
conditions.33 In HIT/ITT, these aggregates occur systemically and
lead to a permanent obstruction of the pulmonary microcirculation.
In contrast, signaling via the Ca2/CalDAG-GEFI/Rap1 signaling
module is critical in the initiation of FcRIIA-dependent platelet
activation. Deficiency in CalDAG-GEFI results in (1) a marked
right shift in the dose-response to FcRIIA agonists and (2) a
significant delay in FcRIIA-mediated platelet activation/aggrega-
tion. Consequently, hFcR mice deficient for CalDAG-GEFI were
completely protected from ITT.
In conclusion, our novel mouse model for ITT closely mimics
experimental HIT and experimental thrombocytopenia and throm-
bosis induced by heparin/VEGF/anti-VEGF complexes. Our model
represents an important step toward more standardized studies on
Figure 6. CalDAG-GEFI deficiency protects from immunoglobulin-induced thrombosis in vivo. (A-B) Platelet counts in whole blood at baseline and 4 hours after infusion
of anti-GPIX antibody. (C-D) Representative near-infrared images of lungs extracted from the respective mice 4 hours after anti-GPIX-Alexa750 injection obtained with a
LICOR Odyssey scanner, software; LICOR Odyssey, Version 3.0. (E-F) Quantitative analysis of the integrated fluorescence density (Adobe Photoshop CS3 extended, Version
10.0.1 Adobe). Results shown are mean fluorescence intensity (a.u.) 
 SEM; n 	 3 to 5. WT (checkered bar), transgenic hFcR (black bar), hFcR pretreated with 75 mg/kg
body weight clopidogrel (light gray bar), and hFcR/CDGI/ (dark gray bar) mice were injected with an Alexa750-labeled antibody against GPIX at a dosage of 0.5 g/g (A,C,E)
or 1 g/g (B,D,F) body weight. ***P  .001. **P  .01. *P  .05. ns indicates not significant.
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the mechanisms underlying platelet activation in ITT, as it
(1) eliminates the need for complicated mouse crosses, (2) depends
on a single antibody instead of preformed immune complexes, and
(3) provides a simple readout for the quantitative visualization of
FcRIIA-dependent thrombosis in vivo. Our studies also provide a
rationale for the documented limited protective effect of P2Y12
inhibitors in HIT patients, and it establishes the Ca2-sensor
CalDAG-GEFI as a promising new target for the intervention
with HIT/ITT.
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